Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline

• DOI: 10.1038/s41380-021-01263-2
• Publication Date: 2021-10-01T03:41:01Z
• Authors: Marco Bucci; Konstantinos Chiotis; Agneta Nordberg
• Keywords: PET Imaging; Cognitive Decline

Abstract For early detection of Alzheimer’s disease, it is important to find biomarkers with predictive value for disease progression and clinical manifestations, such as cognitive decline. Individuals can now be profiled based on their biomarker status Aβ42 (A) or tau (T) deposition neurodegeneration (N). The aim this study was compare the cerebrospinal fluid (CSF) imaging (PET/MR) in each ATN category assess ability predict longitudinal A subset 282 patients, who had at same time PET investigations amyloid-β tracers, CSF sampling, structural MRI (18% within 13 months), selected from ADNI dataset. participants were grouped by diagnosis that time: cognitively normal, subjective memory concern, late mild impairment, AD. Agreement between (amyloid-β-1-42(A), phosphorylated-Tau181(T), total-Tau(N)), (amyloid-β (florbetaben florbetapir)(A), (flortaucipir)(T), hippocampal volume (MRI)(N)) positivity assessed Cohen’s Kappa. Linear mixed-effects models used decline episodic memory. There moderate agreement (Kappa = 0.39–0.71), while only fair T ≤ 0.40, except AD) discordance N across all groups 0.14) found. Baseline predicted irrespective p-Tau181 ( p 0.02). 0.0001), but isolated did not. Isolated Tau observed 2 (0.71% sample). While results similar using imaging, not interchangeable. superior predicting AD continuum 3 years follow-up.